# Klotho Therapeutics, Inc.

> Klotho Therapeutics is a small, privately held biotechnology company developing engineered recombinant versions of alpha-Klotho, a human protein associated with kidney function, cognition and aging biology. Founded by Jim Plante in 2016, the virtual San Diego company raised a $10 million Series A led by Thynk Capital in 2017 to scale manufacturing and pursue an FDA filing, initially in kidney disease. Its public record since then is defined more by patents than clinical readouts: a core recombinant-protein patent issued in 2024 and an antitumor-combination patent issued in 2026, while the company website still frames human trials as future work.

- **Founded:** 2016
- **Headquarters:** San Diego, United States
- **Founders:** Jim Plante (Founder and CEO)
- **Team size:** 2 employees visible on LinkedIn; company size listed as 2-10
- **Products:** Modified recombinant human alpha-Klotho proteins, Klotho measurement and dosing methods, PTBA plus platinum antitumor combinations
- **Notable:** Raised a $10 million Series A led by Thynk Capital in November 2017., Named one of San Diego Venture Group's 2017 Cool Companies, according to the company website., Received U.S. Patent No. 11,932,676 for recombinant Klotho proteins and related manufacturing, measurement and dosing methods in March 2024.

## Products & services

- **Modified recombinant human alpha-Klotho proteins** — Preclinical therapeutic candidates engineered for manufacturability and features such as improved solubility or extended half-life, with kidney disease described as the first priority indication.
- **Klotho measurement and dosing methods** — Patented methods covering assessment of a subject's Klotho level and calculation or timing of recombinant-protein dosing.
- **PTBA plus platinum antitumor combinations** — A patented treatment concept combining cisplatin or another platinum drug with PTBA or a PTBA prodrug for cancer treatment.

## Achievements

- Raised a $10 million Series A led by Thynk Capital in November 2017.
- Named one of San Diego Venture Group's 2017 Cool Companies, according to the company website.
- Received U.S. Patent No. 11,932,676 for recombinant Klotho proteins and related manufacturing, measurement and dosing methods in March 2024.
- Received U.S. Patent No. 12,544,350 for PTBA-plus-platinum antitumor methods in February 2026.
- Maintained international patent activity, including an Australian divisional application published in November 2024.

## Latest updates

- **2024-03** — U.S. Patent No. 11,932,676 issued to Klotho Therapeutics for recombinant Klotho proteins and related methods.
- **2024-11** — Australian application AU2024259844A1, covering products and methods for assessing and increasing Klotho protein levels, was published.
- **2026-02** — U.S. Patent No. 12,544,350 issued for antitumor treatment methods combining a platinum drug with PTBA or a prodrug.

## Links

- Website: https://www.klotho.com/
- LinkedIn: https://www.linkedin.com/company/klotho-therapeutics-inc
- Twitter/X: https://twitter.com/klothobeta
- YouTube: https://www.youtube.com/@klothomarketing5657/videos
- Facebook: https://www.facebook.com/klothotherapeutics/

---

Profile page: https://yespress.io/klotho-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-08-22